ME Therapeutics Holdings Inc.
METX
CNSX
| 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -36.26% | 16.46% | -2.92% | 1.87% | -79.96% |
| Total Depreciation and Amortization | -3.86% | 8.95% | -2.06% | 6.01% | 27.97% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -30.77% | -23.53% | -19.05% | -12.50% | -84.21% |
| Change in Net Operating Assets | 178.34% | -3,170.00% | -95.70% | 9.15% | 223.12% |
| Cash from Operations | 12.49% | -8.78% | -29.31% | 4.94% | -29.90% |
| Capital Expenditure | 100.00% | -1,708.33% | 96.31% | -424.19% | 94.24% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | 100.00% | -- |
| Cash from Investing | 100.00% | -1,708.33% | 96.31% | 31.00% | 56.23% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | -0.60% | -1.84% | 0.00% | 0.00% |
| Issuance of Common Stock | -- | -100.00% | -- | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 0.82% | -110.18% | 1,107.56% | -2.59% | -101.61% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 18.64% | -153.69% | 49.60% | 9.56% | -152.53% |